Taxotere Approved in Canada for Advanced Breast Cancer and NSCLC

September 1, 1995

COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel) has received approval from the Canadian Health Protection Branch for use as second-line treatment of advanced breast and non-small-cell lung cancer (NSCLC). The new drug submission was based on clinical trials involving more than 800 patients worldwide.

COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc.'s Taxotere (docetaxel)has received approval from the Canadian Health Protection Branchfor use as second-line treatment of advanced breast and non-small-celllung cancer (NSCLC). The new drug submission was based on clinicaltrials involving more than 800 patients worldwide.